KR102773176B1 - 암 치료용 안티-서비빈 항체 - Google Patents

암 치료용 안티-서비빈 항체 Download PDF

Info

Publication number
KR102773176B1
KR102773176B1 KR1020187009445A KR20187009445A KR102773176B1 KR 102773176 B1 KR102773176 B1 KR 102773176B1 KR 1020187009445 A KR1020187009445 A KR 1020187009445A KR 20187009445 A KR20187009445 A KR 20187009445A KR 102773176 B1 KR102773176 B1 KR 102773176B1
Authority
KR
South Korea
Prior art keywords
seq
antibody
chain variable
variable region
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187009445A
Other languages
English (en)
Korean (ko)
Other versions
KR20180042431A (ko
Inventor
로버트 에이. 펜스터메이커
마이클 제이. 치에시엘스키
Original Assignee
헬스 리서치 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헬스 리서치 인코포레이티드 filed Critical 헬스 리서치 인코포레이티드
Publication of KR20180042431A publication Critical patent/KR20180042431A/ko
Application granted granted Critical
Publication of KR102773176B1 publication Critical patent/KR102773176B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187009445A 2015-09-04 2016-09-06 암 치료용 안티-서비빈 항체 Active KR102773176B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214242P 2015-09-04 2015-09-04
US62/214,242 2015-09-04
PCT/US2016/050391 WO2017041092A2 (en) 2015-09-04 2016-09-06 Anti-survivin antibodies for cancer therapy

Publications (2)

Publication Number Publication Date
KR20180042431A KR20180042431A (ko) 2018-04-25
KR102773176B1 true KR102773176B1 (ko) 2025-02-27

Family

ID=58188638

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187009445A Active KR102773176B1 (ko) 2015-09-04 2016-09-06 암 치료용 안티-서비빈 항체

Country Status (9)

Country Link
US (3) US10167340B2 (enExample)
EP (1) EP3344287B1 (enExample)
JP (1) JP6831836B2 (enExample)
KR (1) KR102773176B1 (enExample)
CN (1) CN108883163B (enExample)
AU (1) AU2016318158B2 (enExample)
DK (1) DK3344287T3 (enExample)
ES (1) ES2883128T3 (enExample)
WO (1) WO2017041092A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3203732A1 (en) * 2020-12-31 2022-07-07 Health Research, Inc. Anti-survivin antibodies for treatment of autoimmune diseases
US20250018038A1 (en) * 2021-10-06 2025-01-16 The University Of Chicago Survivin targeting polypeptides for detection and treatment of cancer
CN120028549B (zh) * 2023-11-23 2025-11-28 爱威科技股份有限公司 检测丙型肝炎病毒核心蛋白结合蛋白6的试剂盒及应用
CN120025432B (zh) * 2023-11-23 2026-04-21 爱威科技股份有限公司 Hcbp6单克隆抗体及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN122080196B (zh) * 2026-04-23 2026-07-24 北京溯本源和生物科技有限公司 一种抗禽流感病毒h7亚型血凝素蛋白的单克隆抗体及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014744A2 (en) * 2004-07-23 2006-02-09 University Of Massachusetts Compounds that inhibit hsp90 protein-protein interactions with iap proteins
US20140234350A1 (en) * 2013-02-14 2014-08-21 Cedars-Sinai Medical Center Ovarian cancer vaccines and vaccination methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69739105D1 (de) * 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
JP2003529554A (ja) * 1999-12-21 2003-10-07 エール ユニヴァーシティ サバイビンによる血管形成の促進
CA2499891A1 (en) * 2002-10-03 2004-04-15 Large Scale Biology Corporation Multimeric protein engineering
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
AU2007230868B2 (en) * 2006-01-13 2012-02-02 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
PE20130588A1 (es) 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
US8580269B2 (en) 2007-07-19 2013-11-12 Health Research, Inc. Survivin peptides for autoimmune therapies
CA2694011C (en) * 2007-07-19 2016-01-12 Health Research, Inc. Survivin peptides as cancer vaccines
JP5812418B2 (ja) * 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
CN104098696A (zh) * 2013-04-07 2014-10-15 中美华世通生物医药科技（武汉）有限公司 一种抗血管内皮生长因子的单克隆抗体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014744A2 (en) * 2004-07-23 2006-02-09 University Of Massachusetts Compounds that inhibit hsp90 protein-protein interactions with iap proteins
US20140234350A1 (en) * 2013-02-14 2014-08-21 Cedars-Sinai Medical Center Ovarian cancer vaccines and vaccination methods

Also Published As

Publication number Publication date
KR20180042431A (ko) 2018-04-25
EP3344287A4 (en) 2019-04-24
WO2017041092A2 (en) 2017-03-09
US20190119398A1 (en) 2019-04-25
EP3344287A2 (en) 2018-07-11
WO2017041092A3 (en) 2017-05-11
US10167340B2 (en) 2019-01-01
CN108883163B (zh) 2022-04-15
CA2997103A1 (en) 2017-03-09
JP2018529672A (ja) 2018-10-11
JP6831836B2 (ja) 2021-02-17
US11773181B2 (en) 2023-10-03
DK3344287T3 (da) 2021-07-19
CN108883163A (zh) 2018-11-23
ES2883128T3 (es) 2021-12-07
AU2016318158A1 (en) 2018-04-05
EP3344287B1 (en) 2021-05-26
US10738129B2 (en) 2020-08-11
AU2016318158B2 (en) 2022-09-15
US20200377613A1 (en) 2020-12-03
US20170066837A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
JP7464764B2 (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
KR102942600B1 (ko) 항-pd-1 항체, 이의 항원-결합 단편 및 이의 약학적 용도
US11773181B2 (en) Anti-survivin antibodies for cancer therapy
WO2017215585A1 (zh) 抗cd47单克隆抗体及其应用
CN109311978B (zh) Dsg2单克隆抗体和其用途
JP2015024994A (ja) ＤＡＲＰｉｎを含む二重特異キメラ蛋白質
US20240190986A1 (en) Mesothelin binding molecule and application thereof
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
CN114685667B (zh) 间皮素结合分子及其应用
CA2997103C (en) Anti-survivin antibodies for cancer therapy
RU2844869C1 (ru) Антитела против ror1 и родственные биспецифичные связывающие белки
US11970533B2 (en) Bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1 (PD-L1)
RU2807484C2 (ru) Антитело к pd-1, его антигенсвязывающий фрагмент и его фармацевтическое применение
CN121181696A (zh) 一种治疗肿瘤的抗体及其应用
HK40051455B (en) Anti-pd-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601